LONDON (Alliance News) - Horizon Discovery Group PLC Monday said it has been selected to act as a core facility by the Tri-Institutional Therapeutics Discovery Institute, meaning it will provide single and combination drug profiling followed by confirmatory secondary assay services to the institute.
In a statement, the provider of research tools and services to genomics research companies and personalized medicines developers said it will get up to USD500,000 for work it will do in 2015 and 2016, and there is the option for additional collaboration work orders after that.
Horizon will utilize its combination High Throughput Screening platform and Chalice analytics software to screen and analyze potentially thousands of small-molecule drugs, therapeutic antibodies or proteins in combination to identify synergistic or antagonistic interactions. Horizon will also provide a range of optimized cellular assays as follow-ups to identify drug target activity. The first programs are forecast to start in the second half of 2015.
The Tri-Institutional Therapeutics Discovery Institute is a partnership among three scientific and medical institutions that works to more effectively develop therapeutics that arise from discoveries made in basic science labs. The institutions are the Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College.
Horizon Discovery shares were up 1.4% at 226.00 pence Monday morning.
By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
